Literature DB >> 28845462

Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells.

Yunlong Qin1, Christina Hutson1, Xianfu Wu1, Jingyao Xu2, Darin Carroll1.   

Abstract

Cancer immunosurveillance is an important host protection process, monitoring the presence of irregular cells that could potentially transform into tumor cells, effectively clearing the body of transformed tumor cells at their earliest stages, and thus maintaining regular cellular homeostasis. Natural killer (NK) cells are effector lymphocytes of the innate immune system, playing a critical role in surveillance for tumor cells, while also eliminating virally infected cells. The significance of the anti-tumor role of NK cells was recently further verified by findings that immunosuppression in most cancer patients is not perceptible until late stages. NK cells express the low-affinity Fc-activating receptor, CD16, and the inhibitory receptor, killer cell immunoglobulin-like receptor (KIR). Consequently, activation of NK cells is determined by the balance of inhibitory and activating receptor stimulation. Here, we propose establishing an induced pluripotent stem cell (iPSC)-derived NK cell line with KIR gene knockout or knockdown as a possible regimen to treat and prevent cancer. We further postulate that an optimal mixture of NK iPSCs with and without KIR gene knockout, would reach a maximum antitumor activity, with minimal side effects. We also discuss the possible advantages of KIR-knockout NK iPSCs for adoptive immunotherapy in patients with cancer.

Entities:  

Keywords:  Immunosurveillance; Induced Pluripotent Stem Cells; Killer Cell Immunoglobulin-like Receptor; Natural Killer Cell

Year:  2016        PMID: 28845462      PMCID: PMC5568640     

Source DB:  PubMed          Journal:  Enliven J Stem Cell Res Regen Med        ISSN: 2379-5751


  50 in total

1.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors:  Larry Zeitlin; James Pettitt; Corinne Scully; Natasha Bohorova; Do Kim; Michael Pauly; Andrew Hiatt; Long Ngo; Herta Steinkellner; Kevin J Whaley; Gene G Olinger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 3.  Passive immunotherapy of cancer in animals and man.

Authors:  S A Rosenberg; W D Terry
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

Review 4.  Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.

Authors:  T Tonn; S Becker; R Esser; D Schwabe; E Seifried
Journal:  J Hematother Stem Cell Res       Date:  2001-08

5.  Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.

Authors:  G Maki; H G Klingemann; J A Martinson; Y K Tam
Journal:  J Hematother Stem Cell Res       Date:  2001-06

6.  Interleukin-2 driven nuclear translocation of prolactin in cloned T-lymphocytes.

Authors:  C V Clevenger; A L Sillman; M B Prystowsky
Journal:  Endocrinology       Date:  1990-12       Impact factor: 4.736

7.  Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes.

Authors:  Matthew E Brown; Elizabeth Rondon; Deepika Rajesh; Amanda Mack; Rachel Lewis; Xuezhu Feng; Laura Jo Zitur; Randall D Learish; Emile F Nuwaysir
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

8.  Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.

Authors:  Y K Tam; J A Martinson; K Doligosa; H-G Klingemann
Journal:  Cytotherapy       Date:  2003       Impact factor: 5.414

Review 9.  Advantages and clinical applications of natural killer cells in cancer immunotherapy.

Authors:  Erik Ames; William J Murphy
Journal:  Cancer Immunol Immunother       Date:  2013-08-30       Impact factor: 6.968

10.  An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.

Authors:  Cécile Badoual; Pierre-Louis Bastier; Hélène Roussel; Marion Mandavit; Eric Tartour
Journal:  Oncoimmunology       Date:  2013-11-14       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.